Corcept Therapeutics
CORT
97 hedge funds and large institutions have $215M invested in Corcept Therapeutics in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 12 closing their positions.
508% more call options, than puts
Call options by funds: $675K | Put options by funds: $111K
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
33% more capital invested
Capital invested by funds: $161M → $215M (+$53.5M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 98 → 97 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.53M |
| 2 |
D.E. Shaw & Co
New York
|
+$693K |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$685K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$563K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$543K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.29M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$932K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$737K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$496K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$418K |
CORT Hedge Fund Activity: Q4 2015 in Review
97 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2015, worth a combined $215M — up 33% from $161M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CORT and 11 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 38 added.
The largest buyer was Ingalls & Snyder LLC, adding an estimated $1.53M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.29M.
- 97 institutional investors held Corcept Therapeutics (CORT) as of Q4 2015, down from 98 in Q3 2015.
- Funds reported $215M of Corcept Therapeutics stock for Q4 2015, up 33% quarter-over-quarter.
- 11 funds opened new Corcept Therapeutics positions in Q4 2015 and 12 closed out, a net change of -1 holder.
- The largest Corcept Therapeutics buyer in Q4 2015 was Ingalls & Snyder LLC, an estimated $1.53M added.
- The largest Corcept Therapeutics seller in Q4 2015 was T. Rowe Price Associates, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2015.